Strategy

Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval.

Pharm Exec sits down with CEO Atsushi Nagahisa to explore how culture can maximize the value of an inherited portfolio

Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma - but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda.

Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?

Pharm Exec sits down with Steve Collis, CEO of AmerisourceBergen to discuss his agenda for retooling the drug distribution giant.

Success in the emerging markets depends significantly on navigating the myths and mental traps.

The time is right for industry to overcome its social media phobia once and for all.

Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?

Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.

Especially when payers come to the table holding the best cards - leaving industry second-guessing its strategy.

When it comes to the emerging markets, executing a few key elements of success are more important than ever.

Why does the match against medicines compliance always seem to end in an easy knockout?

A Q&A with Kristin Peck, the drugmaker's Executive Vice President, Worldwide Business Development and Innovation.

No one doubts the importance of health expenditures ? but then, euros, like dollars, don't grow on trees

Social media now gives companies a plethora of creative ways to digitally spread recent company news and keep customers informed

When faced with legislative scrutiny, be prepared, be truthful, and don't be afraid to say 'I don't know'...

A Q&A with Andrew Webber, President and CEO of the National Business Coalition on Health

Pfizer's crizotinib development program combined organization, art, and science-and a large dose of unforeseen risk

The objective is to make most cancers a curable, chronic condition. But with soaring costs, crowded therapeutic competition, and new diagnostic reimbursement challenges ahead, can industry deliver?

The payoff is superior performance in key areas such as clinical trials

Patent expiries are inevitable, but brand teams should look to graduate the sales curve

Suggestions for testing new ways of addressing difficult issues of risk

With an emphasis on short-term objectives rather than long-term goals, pharma is missing a huge opportunity in applying market science to drive adherence

Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities

Putting science front-and-center in the design of patient adherence programs can lead to a better understanding of the commitment required to get patients to take their medicine

There's been much talk of how US health reform will impact physicians, patients, and insurance companies. But how will it affect the often overlooked specialty drug market?

Brand managers choosing to advertise an anti-depressant on "Criminal Minds" may not be making the best choice. New methodologies reveal "Law & Order: Special Victims Unit" along with "The Bachelor" to be shows favored by depressives

Tracking, monitoring, and trend evaluation is not enough. Companies must now do more than assess what happened and why.

Will Roche's precedent push the regulatory community to create standards that will level the playing field for all contenders?

Marketers need to understand how informal influencers are beginning to replace traditional channels as the favored way for doctors to receive product information from drug manufacturers, and, in turn, how best to leverage peer influence in designing effective meetings and events